For both assays, at least two blood tests were required from each subject to reduce total variability of LDL-C to 5%.
tion, >41% of American adults are estimated to have increased low-density lipoprotein cholesterol (LDL-C) concentrations requiring further evaluation, and 13 million are likely to require cholesterol-lowering drug therapy [2] . These national guidelines stress the importance of utilizing both diet and drug therapy, if necessary, to achieve LDL-C target concentrations. Therefore, accurate and precise estimations of patients' LDL-C concentrations are necessary to appropriately identify individuals with hypercholesterolemia and to monitor response to diet and drug treatment.
For clinical purposes, LDL-C is generally determined from the Friedewald equation, which assumes that the amount of cholesterol in very-low density lipoproteins (VLDL) can be estimated by dividing the blood triglyceride concentration by a factor of five [3] .The Friedewald equation correlates well with LDL-C concentrations determined by ultracentrifugation if blood triglyceride concentrations are <4.52 mmol/L (400 mg/ dL) [3] .However, the reliability of the LDL-C calculation depends upon the accuracy and precision of total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglyceride measurements. Poor analytic precision in any or all of these measurements will contribute to the variability observed in LDL-C concentrations.
The biologic variability inherent in each of the three lipid measurements will also contribute to the total variability of the LDL-C concentration when the Friedewald equation is used. In particular, the biologic CV of blood triglyceride concentrations may be 20% and may interfere with the reliability of the LDL-C calculation.
Biologic variation is also a major component of the variability in HDL-C measurements, and is frequently in the range of 7-8%. Although analytic variability can often be reduced with methodological advances in the laboratory, sources of error introduced by excessive biologic variability are not easily overcome. [4, 5] , which implies that individual LDL-C readings could vary by up to 40% (±2 SD) from one measurement to the next by chance alone. The usual approach to reduce this variability is to calculate the mean of several serial specimens [6, 7] . For example, to decrease the LDL-C CV to 5%, a level adequate to detect most LDL-C responses to diet and drug therapy, at least two, and as many as five, serial blood specimens may have to be analyzed and averaged [8] .
To we report an interassay CV of 1.5% using specimens frozen at -20 #{176}C, which compares favorably with that reported by others using fresh specimens [9] . However, it is possible that the analytic variability may have been slightly overestimated by performing serial measurements on thawed, rather than fresh, samples.
For each subject, biologic variation (Vi,) was determined for total cholesterol, HDL-C, triglycerides, and LDL-C by using the formula: V1, = V, -V., [13] , where V, is the intraindividual variance of the test observed in the four serial specimens obtained for each subject, and V is the analytic (interassay) variability. The CVs of the biologic and total variability (CVh and CV,, respectively) were determined by taking the square root of the variance for each test, dividing by the patient mean, and multiplying by 100. The mean CV, and CVI, for all subjects are presented in Table 1 .
On the basis of the V, determined for a single specimen, the potential for the mean value derived from serial specimens to reduce total variability of LDL-C was estimated by dividing the observed test variability of a single specimen by the number of serial specimens obtained [14, 15] .
Statistical analysis. The biologic and total variability between calculated and direct LDL-C were compared by using the paired t-test. Correlations between lipid measurements were assessed by using the Pearson correlation coefficient. One-way ANOVA for repeated measures was used to detect differences in dietary adherence scores and weights between visits. In the text, the term "variability" refers to the CV unless otherwise stated. To detect a difference in total variability >1.5%, we determined that a sample of 35 subjects should be sufficient to achieve an a and 13 error of <0.05 and <0.10, respectively. We estimated that smaller differences were unlikely to be clinically relevant for decision making at the clinical level.
Results
The mean age of study subjects was 52 ± 13 years (mean ± SD).
Of the study population, 40% were hypertensive, 14% smoked, 3% had coronary heart disease, and 46% were taking at least one medication (range one to six: mean ± SD 2.5 ± 1.2). The mean body mass index was 27.7 ± 3.2. Food scores and weights were unchanged between study visits. Mean total cholesterol, HDL-C, triglycerides, and LDL-C values for the 35 subjects are shown in Table 1 and reflect mild hypercholesterolemia.
The calculated LDL-C showed a strong correlation with the direct LDL-C assay (r = 0.95, P <0.001), but was, on average, 2.5% lower than the LDL-C measured directly (mean ± SE 4.30 ± 0.10 rnmol/L vs 4.20 ± 0.10, P = 0.002). The CV., for total cholesterol, triglyceride, and HDL-C measurements was <3%, and for the LDL-C calculation was 2.4%. The CV for the direct LDL-C assay was 1.5%.
Mean biologic and total variability computed for each subject are presented in Table 1 . The total CVs for the direct and calculated LDL-C were 6.8% and 7.3%, respectively, and were not significantly different when evaluated by either the CV [direct LDL-C (mean ± SE): 6.8 ± 0.5% vs calculated LDL-C: The biologic variability was higher than the analytic variability for all lipid measurements, and contributed to most of the total variability. This was particularly true for triglycerides, where both the biologic and total variability were -20%.
To assess the relative contribution of total cholesterol, triglycerides, and HDL-C variability to the variability of LDL-C, we determined the correlation between total variability in LDL-C with the variability in these other lipid measurements ( Table 2 ). The total variability of total cholesterol was significantly associated with the variability of calculated LDL-C (r = 0.76, P <0.001). However, the variability in either triglycerides or HDL-C did not contribute significantly to the observed variability in calculated LDL-C determinations.
For the direct LDL-C assay, the variability in total cholesterol was associated with the variability in direct LDL-C measurements, but to a On the basis of the test variability observed for the calculated and the direct LDL-C, we estimated the ability of serial specimens to reduce total variability (Fig. 1) . Averaging the 
Discussiou
Because the calculated LDL-C is derived from total cholesterol, triglycerides, and HDL-C measurements, one may expect that the considerable variability of these three measurements would contribute directly to the observed variability in the calculated LDL-C value. By determining LDL-C directly, the dependence upon three separate and relatively variable lipid measurements, total cholesterol, HDL-C, and triglycerides, is eliminated. In spite of this, however, we found that the direct LDL-C assay did not have significantly lower biologic or total variability of LDL-C compared with the calculated LDL-C. The analytic precision of the direct LDL-C assay was excellent, meeting the precisioncriteria setfortotalcholesterol of 3% and performing better than reported for other direct LDL-C assays involving chemical precipitation methods [16] . The analytic variability for total cholesterol, HDL-C, triglycerides, and the calculated LDL-C measurements were also <3%, comparing favorably with most previously published reports [5] .On the other hand, the high biologic variability present in LDL-C measurements increased the total variability of both the calculated and direct LDL-C estimations.
The total variability (CV) for either measurement was -7%. To reduce this CV for the test to 5%, at least two specimens would be required. Because the direct LDL-C assay did not reduce the total variability for LDL-C, serial specimens remain necessary to reliably determine an individual's LDL-C concentration even when using the direct LDL-C assay.
Because the calculated LDL-C value incorporates the analytic and biologic variability inherent in three separate lipid measurements, it is surprising that the direct LDL-C assay was not more precise than the calculated LDL-C determination.
In This suggests that an accurate and reliable total cholesterol measurement isof primary importance to ensure the accuracy and precision of LDL-C estimations with the Friedewald formula. Recommendations to improve both accuracy and precision of the total cholesterol concentration to CVs of <3% have been formulated [17] , and will help to ensure the reliability of the calculated LDL-C determination. When should the direct LDL-C measurement be ordered? In patients with triglycerides >4.52 mmol/L, VLDL-C cannot be estimated accurately, and the calculated LDL-C becomes less accurate and precise [18] . The calculated LDL-C may also be less reliable in patients with type II diabetes [19] and liver disease [20] , possibly because of the propensity towards increased blood triglycerides in these illnesses. On the other hand, the direct LDL-C assay accurately measures LDL-C with triglyceride concentrations to 9.03 mmol/L or higher [21] . Patients requiring lipid determinations while not fasting may have increased triglyceride concentrations and may also benefit from a direct LDL-C measurement.
Because the performance of the direct LDL-C assay was comparable with the calculated LDL-C determination, cost may be an important factor determining which assay to use. An informal survey of charges in five commercial laboratories in Wisconsin that have used the direct LDL-C assay for >6 months show a range for the direct LDL-C assay from $30 to Similarly, inclusion of more subjects with higher HDL-C concentrations may also increase the variability of the calculated LDL-C value, rendering the direct LDL-C assay a better test. In these settings, further study will be required to determine the comparability of the two assays.
In conclusion, the direct LDL-C assay does not reduce the variation in LDL-C compared with the conventional LDL-C calculation. Therefore, serial specimens are still necessary to accurately assess LDL-C values and gauge response to therapy.
However, because the direct assay is accurate even when triglycerides are increased, and because it allows a less expensive assessment of LDL-C (as an isolated test) than does the standard lipid panel, it appears to have a potentially useful role in lipid disorder management.
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